Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis.

Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis.

Expert Opin Drug Metab Toxicol. 2016 Jan 25;

Authors: Tanaka Y, Senoo A, Fujii H, Baker D

Abstract
INTRODUCTION: Golimumab is a human anti-TNF monoclonal antibody that was derived from human antibody-transgenic mice. Golimumab demonstrated meaningful clinical benefit and tolerable safety in patients with active rheumatoid arthritis (RA) who were methotrexate (MTX)-naïve, or who inadequately responded to MTX or who had previously been treated with a TNF inhibitor. Areas covered: This review summarizes published data on the clinical efficacy and safety for golimumab (including its pharmacodynamic and pharmacokinetic characteristics) from multiple global phase 3 and Japanese phase 2/3 clinical trials. In the long term extension of three Phase 3 studies with subcutaneous golimumab the reported retention rate is high. Expert opinion: Golimumab binds TNF with high affinity and can be delivered subcutaneously every 4 weeks. Like other IgG1 antibodies, FcR functions suggests that antibody dependent cellular cytotoxicity is observed but the contribution of cell lysis to efficacy is unclear. Although anti-TNFα agents made it possible to achieve clinical remission in RA patients, there is still an unmet need to develop treatments that will enable them to discontinue all RA medication and maintain drug-free remission.

PMID: 26811250 [PubMed - as supplied by publisher]

from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/1ZSu6lg
via IFTTT